Aberdeen Group
SRPT icon

Aberdeen Group’s Sarepta Therapeutics SRPT Stock Holding History

Aberdeen Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4M Sell
2,194,948
-123,942
-5% -$2.34M 0.06% 270
2026
Q1 		$50.5M Buy
2,318,890
+67,297
+3% +$1.3M 0.08% 212
2025
Q4 		$48.5M Buy
2,251,593
+268,829
+14% +$5.67M 0.08% 215
2025
Q3 		$38.2M Buy
1,982,764
+740,360
+60% +$13.2M 0.06% 259
2025
Q2 		$21.5M Buy
1,242,404
+592,125
+91% +$25.3M 0.04% 389
2025
Q1 		$41.7M Buy
650,279
+192,584
+42% +$20.3M 0.08% 221
2024
Q4 		$55.3M Buy
457,695
+26,597
+6% +$3.26M 0.1% 194
2024
Q3 		$53.9M Buy
431,098
+101,253
+31% +$14M 0.1% 207
2024
Q2 		$52.1M Buy
329,845
+137,988
+72% +$17.7M 0.1% 200
2024
Q1 		$24.8M Buy
191,857
+45,028
+31% +$5.52M 0.05% 353
2023
Q4 		$14.2M Buy
+146,829
New +$14.1M 0.03% 477
2021
Q3 		– Sell
-5,052
Closed -$393K – 1067
2021
Q2 		$393K Sell
5,052
-2,932
-37% -$222K ﹤0.01% 956
2021
Q1 		$596K Buy
7,984
+238
+3% +$22K ﹤0.01% 899
2020
Q4 		$1.32M Buy
7,746
+215
+3% +$31.9K ﹤0.01% 806
2020
Q3 		$1.06M Buy
7,531
+3,228
+75% +$491K ﹤0.01% 794
2020
Q2 		$690K Sell
4,303
-69
-2% -$9.39K ﹤0.01% 824
2020
Q1 		$428K Buy
4,372
+119
+3% +$13.6K ﹤0.01% 847
2019
Q4 		$549K Buy
4,253
+88
+2% +$8.88K ﹤0.01% 871
2019
Q3 		$314K Buy
+4,165
New +$492K ﹤0.01% 901

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Aberdeen Group's SRPT Position: Q2 2026 in Review

Aberdeen Group reduced its Sarepta Therapeutics (SRPT) stake by 5.3% in Q2 2026, selling an estimated $2.34M and leaving 2,194,948 shares worth $39.4M. The position accounts for 0.06% of the portfolio, ranked #270.

Aberdeen Group first reported a position in SRPT in Q3 2019 and has held it in 19 quarters since. The position peaked at $55.3M in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Aberdeen Group held 2,194,948 shares of Sarepta Therapeutics worth $39.4M as of Q2 2026.
  • Aberdeen Group sold 123,942 Sarepta Therapeutics shares in Q2 2026, an estimated $2.34M.
  • Sarepta Therapeutics made up 0.06% of Aberdeen Group's portfolio in Q2 2026, its #270 holding.
  • Aberdeen Group first reported a position in Sarepta Therapeutics in Q3 2019 and has held it in 19 quarters since.
  • Aberdeen Group's Sarepta Therapeutics position peaked at $55.3M in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.